Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial
Cambridge Health Alliance · Public Health Foundation Enterprises · +7 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
5
total citations
- FWCI
- 80.05
- Percentile
- 100%
- References
- 19
Too recent for citation history.
Authors
19Topics & keywords
Topics
Keywords
- Tenofovir
- Reverse-transcriptase inhibitor
- Phase (matter)
- Phases of clinical research
- Human immunodeficiency virus (HIV)
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.